Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: The mutations and salvage study

Clinical Infectious Diseases

Volumn 42, Issue 10, 2006, Pages 1470-1480

  Gianotti, Nicola ^a,o   Mondino, Vincenzo ^d   Rossi, Maria Cristina ^e   Chiesa, Elisabetta ^b   Mezzaroma, Ivano ^f   Ladisa, Nicoletta ^h   Guaraldi, Giovanni ⁱ   Torti, Carlo ^j   Tarquini, Pierluigi ^k   Castelli, Paula ^l   Di Carlo, Aldo ^g   Boeri, Enzo ^c   Keulen, Wilco ^m   McKenna, Paula ⁿ   Lazzarin, Adriano ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Diagnostica and Ricerca San Raffaele   (Italy)

^d Ospedali Riuniti di Pallanza   (Italy)

^e OSPEDALE CA FONCELLO   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^h POLICLINICO   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j SPEDALI CIVILI   (Italy)

^k Ospedale G Mazzini   (Italy)

^l Reparto di Malattie Infettive   (Italy)

^m Virology Education   (Netherlands)

ⁿ Divisione di Malattie Infettive ^*

^o SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ALGORITHM; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHENOTYPE; PHENOTYPE BASED ALGORITHM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RULE BASED ALGORITHM; STATISTICAL SIGNIFICANCE; VIRTUAL REALITY;

ADULT; ALGORITHMS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; ITALY; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SALVAGE THERAPY; VIRAL LOAD;

EID: 33646447975     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/503568     Document Type: Article

References (13)

1. Meynard JL, Vray M, Morand-Joubert L, et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-36.
2. Haubrich RH, Kemper CA, Hellmann NS, et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS 2005; 19:295-302.
3. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-9.
4. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-93.
5. Cohen CJ, Hunt S, Sension M, et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-88.
6. Cingolani A, Antinori A, Rizzo MG, et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-79.
7. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-18.
8. Harrigan PR, Montaner JS, Wegner SA, et al. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15:1671-7.
9. Torti C, Quiros-Roldan E, Keulen W, et al. Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients. J Infect Dis 2003; 188:194-201.
10. Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis 2005; 40:1828-36.
11. De Luca A, Cingolani A, Di Giambenedetto S, et al. Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis 2003; 187:1934-43.
12. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. Italian Cohort of Antiretroviral-Naive Patients Study Group. AIDS 2000; 14:499-507.
13. Panidou ET, Trikalinos TA, Ioannidis JP. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS 2004; 18:2153-61.